Drugs / METR-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06884345 | Mar 2025 → Dec 2026 expected | ovarian carcinoma | Anhui Provincial Cancer Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | METR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06884345 ↗ |
| Known as | METR | “Dilute METR - 200 mL of NK cells in 37 ℃ 1500 mL of 0.9% sodium chloride physiological saline, intraperitoneal infusion” NCT06884345 ↗ |
| Modality | Cell therapy | “NK cells” NCT06884345 ↗ |
| Route | Other | “intraperitoneal infusion” NCT06884345 ↗ |